File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Kinetics of viral load and antibody response in relation to COVID-19 severity

TitleKinetics of viral load and antibody response in relation to COVID-19 severity
Authors
KeywordsAdaptive immunity; Infectious disease; Molecular biology; Molecular diagnosis; Virology.
Issue Date2020
PublisherAmerican Society for Clinical Investigation. The Journal's web site is located at http://www.jci.org
Citation
Journal of Clinical Investigation, 2020, v. 130 n. 10, p. 5235-5244 How to Cite?
AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent for coronavirus 2019 (COVID-19) pneumonia. Little is known about the kinetics, tissue distribution, cross-reactivity, and neutralization antibody response in patients with COVID-19. Two groups of patients with RT-PCR–confirmed COVID-19 were enrolled in this study: 12 severely ill patients in intensive care units who needed mechanical ventilation and 11 mildly ill patients in isolation wards. Serial clinical samples were collected for laboratory detection. Results showed that most of the severely ill patients had viral shedding in a variety of tissues for 20–40 days after onset of disease (8/12, 66.7%), while the majority of mildly ill patients had viral shedding restricted to the respiratory tract and had no detectable virus RNA 10 days after onset (9/11, 81.8%). Mildly ill patients showed significantly lower IgM response compared with that of the severe group. IgG responses were detected in most patients in both the severe and mild groups at 9 days after onset, and remained at a high level throughout the study. Antibodies cross-reactive to SARS-CoV and SARS-CoV-2 were detected in patients with COVID-19 but not in patients with MERS. High levels of neutralizing antibodies were induced after about 10 days after onset in both severely and mildly ill patients which were higher in the severe group. SARS-CoV-2 pseudotype neutralization test and focus reduction neutralization test with authentic virus showed consistent results. Sera from patients with COVID-19 inhibited SARS-CoV-2 entry. Sera from convalescent patients with SARS or Middle East respiratory syndrome (MERS) did not. Anti–SARS-CoV-2 S and N IgG levels exhibited a moderate correlation with neutralization titers in patients’ plasma. This study improves our understanding of immune response in humans after SARS-CoV-2 infection.
Persistent Identifierhttp://hdl.handle.net/10722/306416
ISSN
2023 Impact Factor: 13.3
2023 SCImago Journal Rankings: 4.833
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWang, Y-
dc.contributor.authorZhang, L-
dc.contributor.authorSang, L-
dc.contributor.authorYe, F-
dc.contributor.authorRuan, S-
dc.contributor.authorZhong, B-
dc.contributor.authorSong, T-
dc.contributor.authorAlshukairi, AN-
dc.contributor.authorChen, R-
dc.contributor.authorZhang, Z-
dc.contributor.authorGan, M-
dc.contributor.authorZhu, A-
dc.contributor.authorHuang, Y-
dc.contributor.authorLuo, L-
dc.contributor.authorMok, CKP-
dc.contributor.authorAl Gethamy, MM-
dc.contributor.authorTan, H-
dc.contributor.authorLi, Z-
dc.contributor.authorHuang, X-
dc.contributor.authorLi, F-
dc.contributor.authorSun, J-
dc.contributor.authorZhang, Y-
dc.contributor.authorWen, L-
dc.contributor.authorLi, Y-
dc.contributor.authorChen, Z-
dc.contributor.authorZhuang, Z-
dc.contributor.authorZhuo, J-
dc.contributor.authorChen, C-
dc.contributor.authorKuang, L-
dc.contributor.authorWang, J-
dc.contributor.authorLv, H-
dc.contributor.authorJiang, Y-
dc.contributor.authorLi, M-
dc.contributor.authorLin, Y-
dc.contributor.authorDeng, Y-
dc.contributor.authorTang, L-
dc.contributor.authorLiang, J-
dc.contributor.authorHuang, J-
dc.contributor.authorPerlman, S-
dc.contributor.authorZhong, N-
dc.contributor.authorZhao, J-
dc.contributor.authorPeiris, JSM-
dc.contributor.authorLi, Y-
dc.contributor.authorZhao, J-
dc.date.accessioned2021-10-22T07:34:17Z-
dc.date.available2021-10-22T07:34:17Z-
dc.date.issued2020-
dc.identifier.citationJournal of Clinical Investigation, 2020, v. 130 n. 10, p. 5235-5244-
dc.identifier.issn0021-9738-
dc.identifier.urihttp://hdl.handle.net/10722/306416-
dc.description.abstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent for coronavirus 2019 (COVID-19) pneumonia. Little is known about the kinetics, tissue distribution, cross-reactivity, and neutralization antibody response in patients with COVID-19. Two groups of patients with RT-PCR–confirmed COVID-19 were enrolled in this study: 12 severely ill patients in intensive care units who needed mechanical ventilation and 11 mildly ill patients in isolation wards. Serial clinical samples were collected for laboratory detection. Results showed that most of the severely ill patients had viral shedding in a variety of tissues for 20–40 days after onset of disease (8/12, 66.7%), while the majority of mildly ill patients had viral shedding restricted to the respiratory tract and had no detectable virus RNA 10 days after onset (9/11, 81.8%). Mildly ill patients showed significantly lower IgM response compared with that of the severe group. IgG responses were detected in most patients in both the severe and mild groups at 9 days after onset, and remained at a high level throughout the study. Antibodies cross-reactive to SARS-CoV and SARS-CoV-2 were detected in patients with COVID-19 but not in patients with MERS. High levels of neutralizing antibodies were induced after about 10 days after onset in both severely and mildly ill patients which were higher in the severe group. SARS-CoV-2 pseudotype neutralization test and focus reduction neutralization test with authentic virus showed consistent results. Sera from patients with COVID-19 inhibited SARS-CoV-2 entry. Sera from convalescent patients with SARS or Middle East respiratory syndrome (MERS) did not. Anti–SARS-CoV-2 S and N IgG levels exhibited a moderate correlation with neutralization titers in patients’ plasma. This study improves our understanding of immune response in humans after SARS-CoV-2 infection.-
dc.languageeng-
dc.publisherAmerican Society for Clinical Investigation. The Journal's web site is located at http://www.jci.org-
dc.relation.ispartofJournal of Clinical Investigation-
dc.subjectAdaptive immunity; Infectious disease; Molecular biology; Molecular diagnosis; Virology.-
dc.titleKinetics of viral load and antibody response in relation to COVID-19 severity-
dc.typeArticle-
dc.identifier.emailPeiris, JSM: malik@hkucc.hku.hk-
dc.identifier.authorityMok, CKP=rp01805-
dc.identifier.authorityPeiris, JSM=rp00410-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1172/JCI138759-
dc.identifier.pmid32634129-
dc.identifier.pmcidPMC7524490-
dc.identifier.scopuseid_2-s2.0-85092219443-
dc.identifier.hkuros328651-
dc.identifier.volume130-
dc.identifier.issue10-
dc.identifier.spage5235-
dc.identifier.epage5244-
dc.identifier.isiWOS:000582387500028-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats